Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mix

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
EJNMMI Physics|April 7, 2025
Open-source phantom with dedicated in-house software for image quality assurance in hybrid PET systemsCarmen Salvador-Ribés, Carina Soler-Pons, María Jesús Sánchez-García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [<sup>68</sup>Ga]Ga-BCY25286Ann-Christin Eder, Mohamed Aymen Omrane, Mohamed El Fakiri, et al.
Theranostics|August 2, 2021
Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studiesSimon K B Spohn, Alisa S Bettermann, Fabian Bamberg, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiationAlexander Rühle, Anca-L Grosu, Nicole Wiedenmann, et al.
Cancers|March 6, 2021
FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation TherapyMontserrat Carles, Tobias Fechter, Gianluca Radicioni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2026
First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [<sup>68</sup>Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findingsAnn-Christin Eder, Christoph-Ferdinand Wielenberg, Mohamed Aymen Omrane, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 17, 2020
The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancerNicole Wiedenmann, Anca-Ligia Grosu, Martin Büchert, et al.
Frontiers in Oncology|June 24, 2022
Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With <i>De Novo</i> Lymph Node-Positive Prostate CancerSimon K B Spohn, Viktoria Birkenmaier, Juri Ruf, et al.
Cancers|July 24, 2021
<sup>18</sup>F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-RadiotherapyMontserrat Carles, Tobias Fechter, Anca L Grosu, et al.
Theranostics|May 28, 2019
Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology referenceConstantinos Zamboglou, Montserrat Carles, Tobias Fechter, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
EJNMMI Physics|April 7, 2025
Open-source phantom with dedicated in-house software for image quality assurance in hybrid PET systemsCarmen Salvador-Ribés, Carina Soler-Pons, María Jesús Sánchez-García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer [<sup>68</sup>Ga]Ga-BCY25286Ann-Christin Eder, Mohamed Aymen Omrane, Mohamed El Fakiri, et al.
Theranostics|August 2, 2021
Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studiesSimon K B Spohn, Alisa S Bettermann, Fabian Bamberg, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiationAlexander Rühle, Anca-L Grosu, Nicole Wiedenmann, et al.
Cancers|March 6, 2021
FDG-PET Radiomics for Response Monitoring in Non-Small-Cell Lung Cancer Treated with Radiation TherapyMontserrat Carles, Tobias Fechter, Gianluca Radicioni, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2026
First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [<sup>68</sup>Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findingsAnn-Christin Eder, Christoph-Ferdinand Wielenberg, Mohamed Aymen Omrane, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 17, 2020
The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancerNicole Wiedenmann, Anca-Ligia Grosu, Martin Büchert, et al.
Frontiers in Oncology|June 24, 2022
Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With <i>De Novo</i> Lymph Node-Positive Prostate CancerSimon K B Spohn, Viktoria Birkenmaier, Juri Ruf, et al.
Cancers|July 24, 2021
<sup>18</sup>F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-RadiotherapyMontserrat Carles, Tobias Fechter, Anca L Grosu, et al.
Theranostics|May 28, 2019
Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology referenceConstantinos Zamboglou, Montserrat Carles, Tobias Fechter, et al.
Pageof 12